Skip Nav Destination
You do not currently have access to this content.
Courtesy of Senorita666/Wikimedia
In 2023, the Food and Drug Administration approved the use of trofinetide to treat Rett syndrome in individuals with pathogenic variants in the MECP2 gene. Rett syndrome is an X-linked neurologic disorder that is more common in females than males.
Genetic testing can identify treatable neurodevelopmental disorders
September 1, 2024
Topics:
